11 results about "Sevelamer" patented technology

The invention relates to a sevelamer carbonate tablet and a preparation method thereof. The preparation method comprises the following steps: carrying out wet granulation on calcium carbonate, microcrystalline cellulose (internally added) and purified water, and carrying out dry granulation on the prepared particles, sevelamer carbonate, microcrystalline cellulose (externally added) and magnesium stearate. The prepared tablet has good moisture uniformity and low hygroscopicity, the storage stability is improved, meanwhile, standing balance is not needed, the preparation time is greatly shortened, the production efficiency is improved, and a new thought is provided for mass production.

The invention provides sevelamer carbonate oral gel as well as a preparation method and application thereof, and belongs to the technical field of veterinary drug preparation. The sevelamer carbonate oral gel is prepared from 3% of sevelamer carbonate, 0.5%-1.0% of gel, 1%-3% of phagostimulant, 0-1.5% of potassium gluconate, 5% of glycerinum and the balance purified water. The sevelamer carbonate oral gel can effectively control hyperphosphatemia of cats suffering from chronic kidney diseases and prevent hypokalemia to a certain extent. The oral gel is convenient to use and only needs to be mixed for administration every day, and the oral gel is added with a cat phagostimulant, so that the mouth feel and the fragrance are improved to better conform to the taste of cats, and the cats can conveniently take medicine by themselves. Compared with tablets, the sevelamer carbonate oral gel has a better serum phosphorus concentration control effect and is more suitable for sick cats to use for a long time.

The invention relates to application of sevelamer. The medicine is particularly applied to treatment of hepatic encephalopathy. According to the method for orally taking the sevelamer compound preparation, the level of ammonia in blood can be remarkably reduced to the normal level, bile acid in the intestinal tract is combined, system inflammation is reduced, and therefore the sevelamer compound preparation is beneficial to curing hepatic encephalopathy, and no obvious side effect is found; the sevelamer oral administration method provided by the invention has a remarkable treatment effect on hepatic encephalopathy, a new candidate treatment medicine is expected to be brought to clinical hepatic encephalopathy, and meanwhile, the range of indications of sevelamer in clinical treatment is widened.

Compositions and principles for use before parturition in the prophylactic treatment of hypocalcemia in ruminant animals include compositions having phosphate binders for the prophylactic treatment of parturient hypocalcemia in ruminant animals. These compositions are presented in unit dosage forms, with one or more doses administered daily to the gastrointestinal tract of the ruminant animal, or in wet form. The composition contains one or more phosphate binders and one or more nutrients selected from minerals, vitamins, and amino acids, as well as a composition that includes an inhibitor of the small intestinal Na-phosphate transporter for the prophylactic treatment of parturient hypocalcemia in ruminant animals. Phosphate binders are selected from aluminum, iron, sevelamer, and lanthanum salts, with either inorganic or organic acids, hydrates thereof, or any mixture thereof.

The present invention relates to an oral formulation comprising sevelamer or a pharmaceutically acceptable salt thereof, and a method for preparing the same. Since the formulation is prepared through fluidized bed granulation, damage to the formulation is reduced and variation caused by abrasion is decreased, such that superior quality can be maintained. In particular, the formulation of the present invention has a smaller granule size while exhibiting increased uniformity, thereby improving medication convenience through reduction in the size of the formulation.

The present application relates to the technical field of preparation of sevelamer carbonate tablets, in particular to a sevelamer carbonate coated tablet and a preparation method thereof. The preparation method of the sevelamer carbonate coated tablet comprises: homogenizing sevelamer carbonate raw materials, a filler and a solvent, then performing spray drying, and then mixing the disintegrating agent and the lubricant uniformly, and then performing tabletting. The hardness of the tablet prepared by the preparation method is above 500N, the surface of the tablet is smooth, the tablet can be normally coated without using a special coating process, and the coated tablet prepared meets the requirements of disintegration time and stability.

The present application relates to the technical field of pharmaceutical preparations, in particular to a powder aerosol intermediate composition and a preparation method thereof, a sodium ciprofloxacin inhalation powder aerosol and an application thereof. The raw and auxiliary materials of the intermediate composition include 1-7 wt% of sodium ciprofloxacin, 92-98 wt% of lactose and not more than 1% of magnesium stearate, in terms of mass percentage fraction; the D 50 of the sodium ciprofloxacin is 1-5 microns; the D 50 of the lactose is 100-150 microns. The intermediate composition can be used for preparing the sodium ciprofloxacin inhalation powder aerosol, and can realize efficient delivery of the sodium ciprofloxacin, improve the delivery efficiency of the sodium ciprofloxacin at a target site, and reduce systemic side effects. The sodium ciprofloxacin inhalation powder aerosol can be used for treating mild diseases such as cystic fibrosis, interstitial pneumonia and idiopathic pulmonary fibrosis, and thus expands the indications of the sodium ciprofloxacin.

The invention discloses a method for determining allylamine in a sevelamer carbonate medicine. The method comprises the following steps: (1) preparing a sevelamer carbonate drug test solution and an allylamine reference solution; (2) respectively carrying out derivatization treatment on the test solution and the reference solution, and during derivatization treatment, adjusting the pH value of a derivatization system by using a buffer solution with the pH value of 8.4-10.8; and (3) determining the derivatization system by using a high performance liquid chromatography. The sevelamer carbonate drug is alkaline, so that the pH value of a test product reaction system is high, the pH value is greatly different from the pH value of a reference product reaction system, the analysis result is unstable, the pH values of a test product derivative system and a reference product derivative system are adjusted to tend to be consistent by adding a buffer solution, so that the influence of the pH value difference on the analysis result is reduced, and the accuracy of the analysis result is improved. The accuracy, repeatability and stability of analysis are improved, the requirements and standards of pharmacopeia on the analysis method are better met, and quality control and safe production of sevelamer carbonate drugs are facilitated.

The application discloses a pharmaceutical composition of sevelamer carbonate and a preparation method thereof. The pharmaceutical composition contains sevelamer carbonate, a stabilizer, an excipient and a wetting agent, and the stabilizer is sucralose. The sevelamer carbonate tablet provided by the application has more stable disintegration time and better compressibility, and can better play the role of a pharmaceutical active ingredient.

The invention discloses a sevelamer carbonate dry suspension and a preparation method thereof.The sevelamer carbonate dry suspension is prepared from, by mass, 94.81%-95.07% of a sevelamer carbonate raw material, 0.11%-1.30% of a suspending aid and other auxiliary materials, and the suspending aid is selected from one or more of sodium carboxymethyl cellulose, a microcrystalline cellulose-sodium carboxymethyl cellulose compound, xanthan gum and hydroxypropyl methylcellulose. Compared with the prior art, the sevelamer carbonate dry suspension has the advantages that the sevelamer carbonate raw material in the sevelamer carbonate dry suspension is high in proportion, and the suspending aid in the sevelamer carbonate dry suspension is low in proportion, so that grit feeling caused by oral administration of the suspension is effectively reduced, the stability and taste of the suspension are improved, the deposition speed of the medicine suspension is reduced, and a patient can uniformly take in the medicine when taking the sevelamer carbonate dry suspension; the method is particularly important for patients suffering from dysphagia or oral sensitivity.

The invention discloses a research method for reducing atherosclerosis risk mechanism, and belongs to the technical field of medicine application. Selecting laboratory mice, feeding the laboratory mice in a 12-hour light-dark period environment, replacing the laboratory mice with high-phosphorus feed, continuously feeding the laboratory mice, monitoring the serum phosphorus level, and grouping the mice which reach the standard; respectively preparing experimental drugs for each group of mice through calcium carbonate, calcium acetate, sevelamer and a composite drug, administering the experimental drugs to the mice in the group, and monitoring the body weight and the serum phosphorus level and adjusting the administration dosage during the period; dynamic monitoring is alternately carried out during administration, and the dynamic monitoring comprises metabolism cage monitoring and blood fat and inflammation detection; collecting blood, aorta and kidney samples after administration; and atherosclerotic plaques and kidney tissues are detected. The invention verifies whether the phosphorus-binding agent phosphorus-reducing drug can reduce the risk of atherosclerosis of hyperphosphatemia patients by reducing the serum phosphorus level, improving blood lipid metabolism, reducing inflammatory response, improving vascular functions and the like, and provides a theoretical basis for clinical treatment.